Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Gambles Oklahoma Opioid Trial Is Better Than Settlement; State Seeks $870m Per Year

Executive Summary

In opening statements, Oklahoma suggests award could be 'just shy of $13bn' if it takes 20 years to fix the problem.

You may also be interested in...



J&J Oklahoma Judgement May Set Benchmark For Massive Opioid Resolution

Judge orders J&J to pay $572m for one-year abatement plan; the state had proposed $12bn over 20-year period. J&J's gamble on a trial has so far not succeeded, since it is now facing more than twice the payout that Purdue agreed to in a settlement.

Behind-The-Scenes Battles As Opioid MDL Jury Trial Nears

Expert witness "battle plan," requests for summary judgment, and squabble over DEA drug distribution data offer preview of the first US bellwether trial against opioid manufacturers, distributors and pharmacies.

Endo And Allergan Could Edge Out Of Opioid Bellwether Trial Spotlight With Proposed Settlements

Companies reach agreements in principal with plaintiffs in bellwether trial in the US multidistrict litigation as court date nears; plaintiffs narrow their claims from 11 to seven.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS125371

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel